Thairm Bio
VC Fund
Thairm Bio is a Trust that invests in early-stage life science companies that show promise in developing breakthrough treatments for diseases with the potential to make a major improvement to patients' lives.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Thairm Bio invests in
Stages Thairm Bio invests in
Countries Thairm Bio invests in
Round sizes
Round size
- Seed
- $2M–$3.3M
- Series A
- $12M–$21M
Investment Focus
Industry
- Health Care 4 (33%)
- Biotechnology 3 (25%)
- Medical 2 (17%)
- Women's 1 (8%)
- Internet 1 (8%)
Stage
- Seed 2 (17%)
- Series A 2 (17%)
- Funding Round 2 (17%)
- Venture - Series Unknown 1 (8%)
Country
- United Kingdom 4 (33%)
- United States 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
EnteroBiotix
|
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $25.7M / Venture - Series Unknown / Apr 29, 2026 | |
3Daughters
|
3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2.7M / Seed / Jul 10, 2024 | |
Phlo
|
Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $11.2M / Venture - Series Unknown / Apr 17, 2024 | |
|
EnteroBiotix
|
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $29.3M / Series B / Apr 04, 2024 | |
|
3Daughters
|
3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2M / Seed / Jan 22, 2024 | |
Microplate Dx
|
Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale. | $3.3M / Seed / Sep 11, 2023 | |
Pneumagen
|
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology. | $10M / Venture - Series Unknown / Jun 01, 2023 | |
|
Phlo
|
Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $12.2M / Series A / Feb 02, 2023 | |
|
Pneumagen
|
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology. | $5.2M / Venture - Series Unknown / Jan 19, 2022 | |
|
EnteroBiotix
|
EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $21.4M / Series A / Sep 07, 2021 | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Thairm Bio invest in?
Thairm Bio invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Thairm Bio's check size?
Thairm Bio typically joins rounds of $2M–$3.3M at Seed and $12M–$21M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Thairm Bio participates in.
When did Thairm Bio last invest?
The most recent investment recorded for Thairm Bio closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
